Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032)

2 minutes read

Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019 2032) — Autism awareness ribbon

DelveInsight’s Autism Spectrum Disorder Market Insights report highlights the expected substantial growth of the Autism Spectrum Disorder Therapeutics Market from 2019 to 2032.

The report provides a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size. Key players in the market include Aardvark Therapeutics, Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo, among others.

Key Takeaways from the Report:

1. The total autism spectrum disorder treatment market size in the 7MM (United States, EU4, and Japan) is projected to increase during the forecast period (2023–2032).

2. Autism spectrum disorder is estimated to be four times more common among boys than girls.

3. Leading companies are developing novel drugs for autism spectrum disorder, including Aardvark Therapeutics, Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo, and others.

4. Promising therapies in the pipeline include ARD-501, Brexpiprazole, JZP541, ML-004 (IR)/(ER) tablet, Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension, Pimavanserin, Cariprazine, AB-2004, RO7017773, L1-79, and more.

Autism Spectrum Disorder Overview: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social communication and interaction, along with restricted and repetitive behavioral patterns. The spectrum encompasses a diverse range of symptoms, varying in severity and skills among individuals with ASD. The report delves into the historical and current patient pool, epidemiological trends, and forecasts for seven major countries.

Market Dynamics:

1. The rising prevalence of ASD diagnoses globally is driving significant growth in the autism spectrum disorder market.

2. The robust autism spectrum disorder pipeline includes potential therapies that are expected to impact the market significantly.

3. Partnerships, licensing agreements, and strategic collaborations between pharmaceutical companies are expected to drive market growth.

4. Increased awareness, improved diagnostic tools, and a growing understanding of the spectrum contribute to higher detection rates.

Pipeline Therapies and Key Companies:

1. ARD-501 (Aardvark Therapeutics)

2. Brexpiprazole (Otsuka Pharmaceutical Development & Commercialization, H. Lundbeck)

3. JZP541 (Jazz Pharmaceuticals)

4. ML-004 (IR)/(ER) tablet (MapLight Therapeutics)

5. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension (Vanda Pharmaceuticals)

6. Pimavanserin (ACADIA Pharmaceuticals)

7. Cariprazine (AbbVie)

8. AB-2004 (Axial Therapeutics)

9. RO7017773 (Hoffmann-La Roche)

10. L1-79 (Yamo Pharmaceuticals)

Market Report Metrics:

• Study Period: 2019–2032

• Coverage: 7MM (United States, EU4, and Japan)

• Key Companies: Aardvark Therapeutics, Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo, among others

• Key Pipeline Therapies: ARD-501, Brexpiprazole, JZP541, ML-004 (IR)/(ER) tablet, Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension, Pimavanserin, Cariprazine, AB-2004, RO7017773, L1-79, and more

Scope of the Report:

1. Assessment of Autism Spectrum Disorder Therapeutic Market

2. Market Dynamics, Forecast Assumptions, and Outlook

3. Competitive Intelligence Analysis

4. Unmet Needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement

The report aims to provide insights into the current and future landscape of the Autism Spectrum Disorder Therapeutics Market, shedding light on market dynamics, emerging therapies, and potential growth opportunities.